Oppenheimer Initiates Coverage On Aquestive Therapeutics with Outperform Rating, Announces Price Target of $8.5
Oppenheimer analyst Francois Brisebois initiates coverage on Aquestive Therapeutics (NASDAQ:AQST) with a Outperform rating and announces Price Target of $8.5.